Bertolaccini ML, Mepani K, Sanna G, Hughes GR, Khamashta MA
Factor XII autoantibodies as a novel marker for thrombosis and adverse obstetric history in patients with systemic lupus erythematosus. [JOURNAL ARTICLE]
Ann Rheum Dis 2006 Oct 4.
PATIENTS AND METHODS: This study comprised 127 patients with SLE. IgG and IgM anti-FXII were tested by an in-house ELISA. One hundred and twenty-three healthy donors comprised the control group.
RESULTS: Fifty-one SLE patients (40%) and nine out healthy controls (7%) were positive for anti-FXII. IgG and IgM anti-Factor XII were frequently found in patients with thrombosis (28% and 13%, respectively). Levels of IgG and IgM anti-FXII were also higher in patients with thrombosis than in the control group (p<0.0001 and p=0.005; respectively). Anti-FXII were also more frequent in patients with arterial thrombosis (31% vs. 4% for IgG and 14% vs. 3% for IgM, respectively) and venous thrombosis than in controls (37% vs. 4% for IgG). IgG anti-FXII were also more frequent in patients with miscarriages and foetal death (35% and 40% vs. 4%). The prevalence of IgM anti-FXII was not different between groups.
CONCLUSION: Anti-FXII are frequent in SLE patients. Their presence is associated with thrombosis and adverse obstetric history making these antibodies a novel marker for the APS.
More from this journal |
